Lead Product(s) : Tartrazine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Neurodawn Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
To Evaluate the Effect of Food on the Pharmacokinetics of Y-4 Tablets in Healthy Subjects
Details : Y-4 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 10, 2025
Lead Product(s) : Tartrazine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Neurodawn Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tartrazine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Neurodawn Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Pharmacokinetics of Y-4 Tablets in Healthy Subjects
Details : Y-4 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 20, 2025
Lead Product(s) : Tartrazine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Neurodawn Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tartrazine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Neurodawn Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Y-4 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 20, 2025
Lead Product(s) : Tartrazine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Neurodawn Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable